Lophius Biosciences
Developing products for the diagnosis of acute infectious and autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | €2.2m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (90 %) | 1 % | 371 % | - | (95 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (964 %) | (1154 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (105 %) | (1023 %) | (1212 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Lophius Biosciences is a pioneering company in the field of immune diagnostic systems. The company focuses on developing advanced molecular diagnostic solutions for life-threatening and highly contagious infectious diseases. Their mission is to transform treatment paradigms and improve patient management through innovative diagnostic technologies.
Lophius primarily serves healthcare providers, research institutions, and laboratories that require precise diagnostic tools to manage infectious diseases. The company operates in the in-vitro diagnostics (IVD) market, which involves tests done on samples such as blood or tissue that are taken from the human body. This market is crucial for disease detection, monitoring, and management.
The business model of Lophius revolves around research, development, and commercialization of diagnostic kits. One of their flagship products is a CE-marked diagnostic kit for Cytomegalovirus (CMV), which is used to personalize the management of transplant patients by assessing their risk of CMV disease. This product is already in the market and generating revenue.
Lophius makes money by selling these diagnostic kits to healthcare providers and research institutions. They also likely generate revenue through partnerships and collaborations with other companies and institutions in the healthcare sector.
In summary, Lophius Biosciences is a key player in the immune diagnostics field, offering innovative solutions to improve the management of infectious diseases. Their focus on personalized medicine and advanced diagnostic technologies positions them well in the growing IVD market.
Keywords: Immune diagnostics, molecular diagnostics, infectious diseases, in-vitro diagnostics, healthcare, CMV, tuberculosis, personalized medicine, research, technology.